210 related articles for article (PubMed ID: 15711261)
1. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
3. [Screening of cancer of the prostate: study in a Spanish population].
Herrero Payo JA; Montes Díaz MJ; Páez Borda A; Sánchez Sánchez E; Moreno Valle JA; Berenguer Sánchez A
Arch Esp Urol; 1996; 49(6):595-606. PubMed ID: 8929102
[TBL] [Abstract][Full Text] [Related]
4. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
[TBL] [Abstract][Full Text] [Related]
5. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
Eggener SE; Roehl KA; Catalona WJ
J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
[TBL] [Abstract][Full Text] [Related]
6. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
Ito K; Kubota Y; Yamamoto T; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
Cancer; 2001 Feb; 91(4):744-51. PubMed ID: 11241242
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
8. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
[TBL] [Abstract][Full Text] [Related]
9. Digital rectal examination is barrier to population-based prostate cancer screening.
Nagler HM; Gerber EW; Homel P; Wagner JR; Norton J; Lebovitch S; Phillips JL
Urology; 2005 Jun; 65(6):1137-40. PubMed ID: 15922431
[TBL] [Abstract][Full Text] [Related]
10. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG; Pileblad E
J Urol; 2003 May; 169(5):1720-3. PubMed ID: 12686817
[TBL] [Abstract][Full Text] [Related]
11. [Screening for early detection of prostate cancer (first experience in Israel)].
Neheman A; Shotland Y; Metz Y; Stein A
Harefuah; 2001 Jan; 140(1):4-10, 88, 87. PubMed ID: 11242898
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam.
Beemsterboer PM; de Koning HJ; Kranse R; Trienekens PH; van der Maas PJ; Schröder FH
J Urol; 2000 Oct; 164(4):1216-20. PubMed ID: 10992369
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey.
Bunker CH; Patrick AL; Konety BR; Dhir R; Brufsky AM; Vivas CA; Becich MJ; Trump DL; Kuller LH
Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):726-9. PubMed ID: 12163325
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
Berger AP; Deibl M; Steiner H; Bektic J; Pelzer A; Spranger R; Klocker H; Bartsch G; Horninger W
Prostate; 2005 Aug; 64(3):240-5. PubMed ID: 15712213
[TBL] [Abstract][Full Text] [Related]
15. Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer.
Galić J; Karner I; Cenan L; Tucak A; Hegedus I; Pasini J; Bilandzija-Peranović M; Mihaljević S
Coll Antropol; 2003; 27 Suppl 1():61-6. PubMed ID: 12955893
[TBL] [Abstract][Full Text] [Related]
16. Prostate carcinoma among men with human immunodeficiency virus infection.
Crum NF; Spencer CR; Amling CL
Cancer; 2004 Jul; 101(2):294-9. PubMed ID: 15241826
[TBL] [Abstract][Full Text] [Related]
17. [Results of a screening program for prostatic cancer].
Martín Oses E; Luján Galán M; Sánchez Sánchez E; Herrero Payo A; Páez Borda A; Berenguer Sánchez A
Actas Urol Esp; 1999 Apr; 23(4):287-95. PubMed ID: 10394648
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing use of the prostate-specific antigen screening test in primary care.
Moran WP; Cohen SJ; Preisser JS; Wofford JL; Shelton BJ; McClatchey MW
Am J Manag Care; 2000 Mar; 6(3):315-24. PubMed ID: 10977432
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/dl: results from the cooperative prostate cancer tissue resource.
Datta MW; Dhir R; Dobbin K; Bosland MC; Melamed J; Becich MJ; Orenstein JM; Kajdacsy-Balla AA; Patel A; Macias V; Berman JJ
J Urol; 2005 May; 173(5):1546-51. PubMed ID: 15821483
[TBL] [Abstract][Full Text] [Related]
20. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
